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Abstract
Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate
cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported
overall survival beneﬁt for patients treated with radium-223 and best standard of care (BSoC) when compared with
placebo and BSoC in the ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial. At that time, docetaxel was
the standard ﬁrst-line choice for patients with metastatic CRPC (mCRPC). Since then, the treatment landscape has
changed dramatically with new hormonal agents (abiraterone and enzalutamide) considered to be the ﬁrst-line choice
for many patients. The optimal patient proﬁle for radium-223 in the modern setting, and its best use either in sequence
or in combination with other approved agents are unclear, with few deﬁnitive guidelines available. This article reports
on the views of a group of urologists and medical oncologists experienced in treating patients with mCRPC with
radium-223 in routine clinical practice. The aim is to provide an overview of the current use of radium-223 in the
treatment of patients with mCRPC, and to discuss best practices for patient selection and on-treatment monitoring.
Where agreement was reached, guidance on the optimal use of radium-223 is provided.
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The majority (90%) of patients with castration-resistant prostate
cancer (CRPC) will develop bone metastases, which are associated
with symptomatic skeletal events (SSEs), impaired quality of life,
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the bone microenvironment in a vicious cycle that disrupts the
balance between osteolytic and osteoblastic activity and interferes
with physiologic skeletal remodeling.4,5 First, there is an important
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Guidance for Radium-223 Use in mCRPCin the bone. Next, there is an abnormal bone formation owing to
the release of cytokines from bone matrix and tumor cells that
promote osteoblast differentiation and activity.
Radium-223 dichloride (radium-223), a targeted alpha therapy,
was approved in 2013 for the treatment of patients with metastatic
CRPC (mCRPC) exclusively with symptomatic bone metastases but
without visceral disease and limited lymphadenopathy. This was
based on data from a phase III trial in which patients randomized to
radium-223 and best standard of care (BSoC) demonstrated longer
survival compared with those randomized to placebo and BSoC.6
Radium-223 is 1 of 6 survival prolonging agents currently
approved for the treatment of mCRPC. The others are the taxane-
based chemotherapies, docetaxel7 and cabazitaxel,8 the new hor-
monal therapies, abiraterone9-11 and enzalutamide,12,13 and the
immunotherapy, sipuleucel-T (not used outside of the United
States).14 Evidence-based treatment guidelines provide recommen-
dations for radium-223 use in the mCRPC setting.15-17 The
optimal patient proﬁle for radium-223, and the best use of the agent
either in sequence or in combination with other approved agents is
however, unclear, with few expert consensus opinions available.18,19
This article reports on the views of a group of urologists and
medical oncologists from Europe, Israel, and Canada experienced in
treating patients with mCRPC in routine clinical practice. The aim is
to provide an overview of the current use of radium-223 in the
treatment of mCRPC and to discuss best practices for patient selec-
tion and on-treatment monitoring. Where agreement was reached,
guidance is provided on the contemporary use of radium-223.
Overview of Radium-223, a
Targeted Alpha Therapy
Mode of Action
Radium-223, a bone-seeking calcium mimetic, forms hydroxyap-
atite complexes during bone mineralization in areas of high osteoblast
activity and increased bone turnover around prostate cancer meta-
static lesions.20-22 Radium-223 decays to emit predominantly high
energy alpha particles over a short range (< 1 mm), leading to
cytotoxicity through the production of predominantly unrepairable
DNA double strand breaks in nearby tumor and cells forming the
cancer microenvironment.20-23 By contrast, beta particle-emitting
radionuclides have a comparatively lower energy than radium-223,
resulting in less effective DNA damage, and a longer range and
higher penetration, leading to higher exposure and toxicity to more
distant normal myeloproliferative cells.23-25 Unlike radium-223,
which has demonstrated a survival beneﬁt in mCRPC, beta particle
emitting radionuclides have shown activity exclusively in relation to
bone pain palliation; furthermore, their recent use has diminished.25
Clinical Development
In the pivotal phase III trial (ALpharadin in SYMptomatic Prostate
Cancer [ALSYMPCA]), 921 patients with histologically conﬁrmed
progressive mCRPC and predominant symptomatic bone metastases
(patients with visceral disease or lymph node metastases> 3 cm in the
short-axis diameter were excluded) were randomly assigned (2:1) to
receive 6 injections of radium-223, 50 kBq/kg (55 kBq/kg following
National Institute of Standards and Technology update in 2016)
with BSoC or to receive placebo with BSoC.6 Patients had received
prior docetaxel (57%), or were unﬁt for docetaxel, had declined- Clinical Genitourinary Cancer February 2018docetaxel, or were unable to receive docetaxel for other reasons (43%).
Median overall survival (co-primary endpoint)was longer (14.9 vs. 11.3
months; hazard ratio [HR], 0.70; 95% conﬁdence interval [CI], 0.58-
0.83; P< .001) in patients receiving radium-223 and BSoC compared
with those receiving placebo with BSoC.6 Time to ﬁrst SSE (secondary
endpoint)was longer in the radium-223 arm (HR, 0.66; 95%CI, 0.52-
0.83;P< .001).6,26The short- and long-term safety proﬁle (co-primary
endpoint) was favorable, with low rates ofmyelosuppression,6,27-29 and
meaningful improvements in quality of life measures recorded in pa-
tients in the radium-223 arm.30 Based on these ﬁndings, radium-223
was approved for the treatment of patients with mCRPC, symptom-
atic bone metastases, and no known visceral metastatic disease.
A recent single-arm phase IIIb international early access program
(iEAP) reported no new safety concerns for radium-223 when
administered to patients with mCRPC and symptomatic or
asymptomatic bone metastases in routine clinical practice.31,32 In
subgroup analyses of this study, radium-223 appeared to be more
effective and was equally well-tolerated when given concomitantly
with abiraterone and/or enzalutamide.31 It has also been shown that
radium-223 can be safely combined with bone-supportive agents
including denosumab and bisphosphonates, and external beam
radiation therapy.6,31,33,34 In a further exploratory analysis, overall
survival was reported to be longer in patients receiving radium-223
with concomitant denosumab compared with those receiving
radium-223 without denosumab.31
Contemporary Use of Radium-223
Who Is the Optimal Patient for Radium-223?
The radium-223 label and current prostate cancer treatment
guidelines offer little insight into which patients might receive the
most beneﬁt from treatment in current clinical practice.15,16,35,36
When it was ﬁrst used in the clinic, particularly in EAPs, a propor-
tion of patients (32%-46%) discontinued radium-223 after 1 to 4
cycles.37,38 Most patients enrolled in these programs were quite
advanced in their disease course, were heavily pretreated, and were
unlikely to beneﬁt from any further systemic anti-cancer treatment.
Most had already received chemotherapy, abiraterone or enzaluta-
mide, and other anti-cancer agents. However, the timing and pattern
of metastatic spread in patients with CRPC reveals a window of
opportunity for the use of radium-223 much earlier prior to the onset
of visceral disease (Figure 1).39 The majority (90%) of patients with
CRPC will develop bone metastases and no visceral disease, and are
therefore potential candidates for radium-223 treatment.
Baseline factors including those related to levels of lactate dehy-
drogenase (LDH), prostate-speciﬁc antigen (PSA), alkaline
phosphatase (ALP), hemoglobin, pain, and Eastern Cooperative
Oncology Group performance status may be useful in stratifying
patients with better prognosis and therefore, those who are earlier in
their disease course.31,37,38,40 In post hoc analyses, patients with
good prognostic factors have been shown to be more likely to
complete 6 cycles of radium-223 and, consequently, derive the most
beneﬁt from receiving radium-223.37,38 In relation to symptoms,
the deﬁnition of ‘symptomatic’ used in the ALSYMPCA study
(regular use of analgesic medication [paracetamol to opioid anal-
gesics] or treatment with external beam radiation therapy required
for cancer-related bone pain within the previous 12 weeks)6 is
considered by many clinicians to have been too broad. There is a
Figure 1 Prevalence of Visceral and Bone Metastases Over Time; Window of Opportunity for Radium-223. *Patients With Bone Only
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Daniel Heinrich et alview that it is the presence of bone-predominant disease that is the
more important factor, with symptoms having less importance in
treatment selection. Therefore the use of radium-223 in patients
with asymptomatic bone metastases might also be beneﬁcial. In a
subgroup analysis of the radium-223 iEAP, outcomes for patients
with asymptomatic and symptomatic disease were investigated.31
The frequency of reported adverse events was similar in both sub-
groups. Overall survival (HR, 0.486; 95% CI, 0.325-0.728) and
time to ﬁrst SSE (HR, 0.328; 95% CI, 0.185-0.580) were longer in
radium-223-treated patients with asymptomatic compared with
symptomatic disease.32 However diagnosis of symptoms can be
difﬁcult, as pain is usually underreported by patients and often
recorded by physicians as either present or absent. Many patients
with bone metastases may have symptoms that they do not relate to
pain. For example, a recent large survey conducted by the Inter-
national Prostate Cancer Coalition showed that many patients with
skeletal metastases report increasing difﬁculty in walking and a
reduction in the ability to perform everyday activities (https://www.
menwhospeakup.com/index.php). Patients may also develop
asthenia, anorexia, or even cachexia, which can be related to bone
metastases burden and progression.
Level 1 evidence indicates the use of radium-223 in patients with
CRPC and symptomatic bone metastases (no visceral disease). Although
there is currently an absence of level 1 evidence, there was consensus that
the majority of patients with mCRPC and predominant bone metastases
may be candidates for treatment before the onset of visceral disease. Forexample, patients with bone-predominant mCRPC who are earlier in
their disease course may beneﬁt from radium-223 treatment.
In What Treatment Sequence Should Radium-223 Be
Used?
For a long time, docetaxel was the only systemic treatment option
with proven survival beneﬁt for mCRPC. Subgroup analyses
from the ALSYMPCA trial showed an overall survival beneﬁt for
radium-223 irrespective of prior docetaxel use.41 In further
exploratory analyses, docetaxel administered following radium-223
appeared to be feasible and well-tolerated with no detrimental ef-
fects on overall survival reported.42
However, new hormonal agents currently are considered as ﬁrst-
line options in patients with asymptomatic or mildly symptomatic
mCRPC.15,18 Consequently, the treatment sequence for mCRPC
has changed, moving docetaxel and radium-223 after abiraterone
and/or enzalutamide when these agents are used as ﬁrst-line treat-
ment. In patients progressing on ﬁrst-line new hormonal agents
(with no evidence of visceral disease), for those whose disease is
symptomatic, radium-223 would be an appropriate second-line
choice. Radium-223 with concomitant abiraterone or concomitant
enzalutamide (administered at the discretion of the treating physi-
cian), has been found to be effective in patients with symptomatic
bone metastases in an expanded access setting, and, in the iEAP, in
patients with symptomatic or asymptomatic disase.31,43 Ongoing
randomized clinical trials including Evaluation of Radium-223Clinical Genitourinary Cancer February 2018 - e225
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(NCT02043678) and Prostate Cancer Consortium in Europe trial
III (PEACE III) (NCT02194842) are investigating the ﬁrst-line
combination of radium-223 with abiraterone or enzalutamide in
patients with asymptomatic/mildly symptomatic mCRPC, and will
provide supporting data for the optimal positioning and combina-
tion of radium-223 in the treatment paradigm.
Radium-223 product information, treatment guidelines, and
some experienced clinicians do not exclude the use of radium-223
in ﬁrst-line treatment of some patients with mCRPC and
symptomatic bone metastases (no visceral disease).15,18,35,36,44
Radium-223 may also be considered for some patients (those with
good performance status) as third- or fourth-line treatment options.
With no supporting level 1 data from clinical trials, the optimal
position of radium-223 in the current treatment paradigm is not
established, and decisions as to the timing of its use are left largely to
the clinical judgment of the treating physician (Figure 2).
There is currently no level 1 evidence to establish an optimal sequence
position for radium-223. Despite this, there was, however, consensus
that early administration of radium-223 to patients with predominant
bone metastases (and no visceral disease) progressing on ﬁrst-line
treatment (abiraterone or enzalutamide) maybe be considered as an
option. However, equally, administration of radium-223 in later lines
of treatment may be a suitable and beneﬁcial option for some patientsFigure 2 Summary of Possible Positions for Radium-223 in the Tre
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trials are required before recommendations can be made for adminis-
tering radium-223 in combination with new hormonal therapies.
What Monitoring Should Be Performed for Patients
Receiving Radium-223?
In general, regular on-treatment monitoring of patients with
mCRPC is recommended.18,44 This would include clinical and
laboratory assessments such as blood counts (neutrophil, platelet,
and hemoglobin), assessment of pain and pain medication, Eastern
Cooperative Oncology Group performance status, serum markers
(PSA, LDH, and ALP), and imaging.
Which Biomarkers Might Be Useful for Monitoring
Patients Receiving Radium-223?
Rising PSA levels, and particularly short PSA doubling time, may
indicate tumor growth. However, in general, cautious interpretation
of PSA data is recommended, as a ﬂare phenomenon has been
described following the initiation (ﬁrst 2-3 months) of chemo-
therapy and treatment with new hormonal therapies.45-48 PSA
expression has been shown to be regulated by the androgen/
androgen-receptor axis.49,50 Thus, changes in PSA levels can
indicate a tumor response to androgen-receptor targeting, for
example, by new hormonal therapies.9,51 Consequently, PSAatment Sequence for mCRPC. Supporting Level 1 Evidence is
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Table 1 Timing of Assessments for Patients With mCRPC Receiving Radium-223
Baseline 3 Months 6 Months Follow-up Every Cycle
Biomarkers
Total ALP þ þ þ þ (þ)
PSA þ (þ) þ þ
LDH þ þ þ þ þ
Imaging
Bone scintigraphya þ e þ e
CT scana þ (þ) þ þ
Axial MRI þ (þ) (þ) (þ)
Other
Clinical symptoms þ þ þ þ þ
Hematologic
parameters
þ þ þ þ þ
Recommendations agreed by roundtable discussion at the meeting: þ ¼ recommended; (þ) ¼ if clinically indicated;  ¼ not routinely recommended.
Abbreviations: ALP ¼ alkaline phosphatase; CT ¼ computed tomography; LDH ¼ lactate dehydrogenase; mCRPC ¼ metatstatic castration-resistant prostate cancer; MRI ¼ magnetic resonance
imaging; PSA ¼ prostate-speciﬁc antigen.
aBone scintigraphy þ CT scans can be replaced with MRI if available.
Daniel Heinrich et alincreases while on treatment with abiraterone or enzalutamide may
indicate treatment resistance.
Bone-related markers, for example, bone-speciﬁc ALP (a marker
of osteoblastic activity), are also reported to be important prognostic
factors in patients with mCRPC and bone metastases.52,53 In some
studies, serum ALP levels appeared to be a more clinically relevant
biomarker than PSA in patients with prostate cancer with bone
metastases.54,55 The mode of action of radium-223 impacts both on
tumor growth and tumor-induced pathologic osteoblastic bone
growth, and would suggest a primary effect on serum ALP levels.22
In early studies, changes in ALP levels appeared to be a marker of
radium-223 effects.33,56 In the pivotal phase III study, radium-223
treatment signiﬁcantly prolonged time to increase in total ALP
(tALP) levels, and a higher proportion of patients showed a tALP
response ( 30% decrease from baseline) compared with placebo.6
Exploratory analyses from the phase III study investigated the
effect of radium-223 on changes in tALP, PSA, and LDH levels.40
Radium-223 treatment led to a rapid and sustained decrease in
tALP levels from baseline through treatment and follow-up
compared with placebo (where tALP levels increased during the
study). At week 12 (after 3 radium-223 cycles), 87% of patients had
a tALP decrease from baseline compared with 23% of patients
receiving placebo (P < .001). Furthermore, patients receiving
radium-223 who experienced a conﬁrmed tALP decline at week 12
had a longer overall survival than those who did not (HR, 0.45;
95% CI, 0.34-0.61).40 In contrast, radium-223 had a relatively
modest effect on PSA kinetics, with 27% of patients showing a PSA
decline at week 12 compared with 14% in the placebo group
(P ¼ .160).40 Similar ﬁndings on ALP were reported in the radium-
223 iEAP.57
Baseline serum LDH levels were also reported to be prognostic
for survival in patients with mCRPC.40 In the phase III study,
radium-223 also had a signiﬁcant effect on LDH kinetics compared
with placebo, with an LDH decline at week 12 reported in 51% of
patients treated with radium-223 compared with 34% of thosereceiving placebo (P ¼ .003). Furthermore, patients treated with
radium-223 who experienced a conﬁrmed LDH decline at week 12
survived longer than those without a conﬁrmed decline (HR, 0.55;
95% CI, 0.42-0.73).40 It was concluded that without current
predictive markers, ALP or LDH changes could be assessed
dynamically over the radium-223 treatment course.
In summary, PSA is not a reliable marker for radium-223
treatment. The value of ALP as a biomarker for radium-223 re-
quires further validation. There are also several factors to be
considered when proposing the use of a candidate biomarker for
monitoring radium-223 treatment efﬁcacy. First, it is important to
be aware of ﬂare phenomena, which can occur despite the patient
showing a good response to treatment by other parameters. Second,
it is important not to stop radium-223 treatment for increases in
ALP or PSA alone, as currently neither are validated as markers of
progression for radium-223. Finally, it is important to educate
patients on their expectations with regard to radium-223 and PSA
levels, so as not to increase patient anxiety with unnecessary and
sometimes conﬂicting information on serum biomarker levels.
It was agreed that currently there are no validated biomarkers for
monitoring radium-223 efﬁcacy in everyday clinical practice. PSA is
not a useful surrogate for monitoring radium-223 efﬁcacy, but changes
in ALP dynamics may prove to be more useful. It was agreed that
biomarkers should be regularly assessed in patients receiving radium-
223 for information purposes and used in the context of other assess-
ments to establish clinical progression (summarized in Table 1).
Which Imaging Techniques Should Be Used for
Monitoring Patients Receiving Radium-223?
Imaging methods for patients with mCRPC and bone metastases
are summarized in Table 2.
Data on the best imaging methods for monitoring patients on
radium-223 are currently lacking. In addition, imaging was not
mandated in the ALSYMPCA study.6 A number of phase I and II
clinical trials with imaging integral to the primary objective areClinical Genitourinary Cancer February 2018 - e227
Table 2 Imaging Techniques in mCRPC With Bone-predominant Metastases
Technique Advantages Limitations
99mTc bone scan Only technique that can identify areas of:
 Highest bone turnover (may indicate metastases)58
 Radium-223 accumulation58
 Low speciﬁcity58
 Negative scan not sufﬁcient to exclude metastases59
 Flare phenomenon44
18F-NaF PET
 Greater sensitivity than bone scan15
 Quantitative; absolute determination of activity per unit
volume of tissue60
 Not widely used for monitoring with radium-22358
 Lack of data leading to controversy about how results should
be used: phase III trials to date used only bone scans15
CT
 High level of anatomic detail15  Flare phenomenon44
MRI
 Axial skeleton
 Whole-body
 Potential to detect metastasis early in bone growth, before
gross bone remodeling is detected by bone scan/CT60
 Concurrent bone and node metastasis screening (whole body)
 Many centers still in feasibility stage of comparing whole-body
MRI to established techniques60
 Added value over bone scan (eg, earlier and more
reliable detection of metastasis) not yet proven44
PET/CT novel tracers
(Choline, PSMA, Fluciclovine)  Data suggest accurate detection of recurrence15
 Concurrent bone and node metastasis screening
 Need validation with randomized prospective trials15
 Added value over bone scan (eg, earlier and more
reliable detection of metastasis) not yet proven15
 Data on new tracers is lacking
Abbreviations: CT ¼ computed tomography; 18F ¼ 18F-ﬂuoride; MRI ¼ magnetic resonance imaging; NaF ¼ sodium ﬂuoride; PET ¼ positron emission tomography; PSMA ¼ prostate-speciﬁc
membrane antigen; 99mTc ¼ technetium-99m.
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e228ongoing in patients with CRPC with bone metastases under
radium-223 treatment, including measuring response (see
Supplemental Table 1 in the online version).
Disease monitoring in bone is problematic, with ﬂare phenomena
on computed tomography (CT) and bone scans reported.44,61
Whole body magnetic resonance imaging (MRI) and positron
emission tomography imaging are considered to be the best options
for assessing the extent of disease, whereas MRI appears to be most
promising for measuring response,62 although this has not been
validated for radium-223. However, MRI is not in regular clinical
use owing to restricted resources. Imaging practice is, therefore,
currently undergoing major changes in this setting.
Bone progression during radium-223 treatment has been shown
to be rare.61 Frequent bone scintigraphy may therefore not be
required, and unnecessary imaging should be avoided. A recent
multicenter study retrospectively evaluated CT and bone scintig-
raphy response in 130 patients treated with radium-223.61 The
authors concluded that bone progression was rare (6%), although a
ﬂare (pain and/or radiologic) phenomenon may be noted at 3
months and should not be confused with progression. CT imaging
after 3 and 6 doses of radium-223 was suggested to rule out visceral
disease progression that may necessitate discontinuing radium-223
in favor of chemotherapy or a new hormonal agent. CT scan data
can also be used in patients with widespread bone metastases to
screen for signs of potentially critical lesions in the spine, which
should be further investigated with MRI.63
Discussion on the timing for imaging while receiving radium-223 is
summarized in Table 1. It was agreed that a bone and CT scan should
always be performed before treatment with radium-223 and at 6
months to provide a new baseline after treatment. A CT scan at 3
months was recommended only if clinically indicated, to check for signs
of progression (visceral disease). The majority also agreed, that if- Clinical Genitourinary Cancer February 2018available, a whole body MRI scan could be used to replace bone and CT
scans. It was agreed that currently, in the absence of prospective data,
imaging should only be performed to screen for visceral disease and
suspected spinal cord compression, and not to evaluate response to
radium-223.
When Should Radium-223 Be Stopped?
Discussion of when to stop radium-223 was held in the context of
the recommendations from the Advanced Prostate Cancer Consensus
Conference (APCCC). The APCCC general criteria for stopping a
treatment recommends 2 out of the following 3 criteria: PSA pro-
gression, radiographic progression, and clinical progression.44 In the
event of unequivocal progression of soft tissue disease or development
of visceral metastases without PSA progression or clinical deteriora-
tion, then treatment with radium-223 should be stopped and alter-
native therapy commenced. A biopsy taken to rule out second
malignancy or small-cell histology should be considered. Men with
mCRPC can often have worsening bone pain related to a nonma-
lignant process (degenerative disorders or osteoporotic fractures).
Similarly, fatigue can be a side-effect of treatment and not a sign of
disease progression.
As previously discussed, during the ﬁrst course of radium-223,
some patients may experience a ﬂare phenomenon either as pain,
a PSA rise, or a radiologic ﬂare, all unrelated to disease progression.
Thus, physicians should consider that only radiologic visceral pro-
gression as per CT scan (and suspected spinal cord compression)
should be a clear indication for radium-223 treatment
discontinuation.
In the absence of level 1 data, there was consensus that the APCCC
stopping criteria were helpful and suitable for radium-223 treatment.
However, as PSA is not a reliable marker, the importance of regular
clinical assessment was emphasized.
Daniel Heinrich et alSummary
Patients with mCRPC should ideally be discussed by a multi-
disciplinary team, where the purpose of using radium-223 to
prolong overall survival should be emphasized to both treating
physicians and patients. It is important during treatment that the
opportunity to administer as many of the available life-prolonging
therapies is optimized. Radium-223 must be placed prior to the
onset of visceral disease (lung, liver, or other organ metastases).
Data from ongoing clinical studies may clarify the optimal
placement of radium-223 in the current treatment paradigm. To
date, there are no validated biomarkers for monitoring treatment
on radium-223, and biomarker information would be best used in
the context of other assessments to establish clinical progression.
Repeated radiologic assessments are best avoided, and, unless
otherwise indicated by clinical assessment, imaging is best used at
the beginning and end of treatment to establish a baseline for
further follow-up.Acknowledgments
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Supplemental Table 1 Clinical Trials of Patients With mCRPC Treated With Radium-223 With Imaging as Primary Objectives
NCT Number (Study)
Estimated
Enrollment
Imaging
Technique
Outcome
(Purpose) Completion
NCT02429804 (phase I) 15 NaF/FDG/PET/MRI Response April 2018
NCT03011749 40 FLT/PET/CT Uptake of FLT in hematologic bone marrow (as a
marker of proliferative activity/toxicity)
January 2019
NCT02964988 (phase II) 43 uPAR PET/CT (tracer: 68Ga-NOTA-AE105) uPAR PET/CT imaging (test applicability of method) January 2019
NCT03062254 (phase II) 10 PET/CT (tracer 68Ga-HBED-CC-PSMA) SUV-max (functional decline in intensity [uptake] as a
surrogate for tumor cell killing)
July 2020
NCT02844647 (phase I) 10 MRI (13Carbon hyperpolarized pyruvate) Metabolic imaging (proof of concept study to image
lactate, bicarbonate and pyruvate)
July 2018
Abbreviations: FGD ¼ 18Flourine-ﬂudeoxyglucose; FLT ¼ 18Flourine-ﬂuorothymidine; 68Ga ¼ 68Gallium; HBED-CC ¼ N,N’ bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N’-diacetic acid;
MRI ¼ magnetic resonance imaging; NaF ¼ 18Fluoride sodium ﬂuoride; PET ¼ positron emission tomography; PSMA ¼ prostate-speciﬁc membrane antigen; uPAR ¼ urokinase plasminogen
activator.
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